# A Cannabinoid-Like Compound Modulates Neuronal Excitability, May Reduce Seizures > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-like-compound-seizure-reduction/ > **Published:** 2022-05-12T13:44:57-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:16:37-04:00 > **Clinical Summary:** Explore how a cannabinoid-like compound seizure reduction approach modulates neuronal excitability and may help reduce seizures. --- **The Cannabinoid-Like Compound, VSN16R, Acts on Large Conductance, Ca2 -Activated K Channels to Modulate Hippocampal CA1 Pyramidal Neuron Firing** In Summary Researchers have recently found a cannabinoid-like compound, VSN16R, which is able to modulate Ca2+- activated potassium channels and may reduce seizure severity. By hyperpolarizing the neurons through the opening of Ca2+- activated potassium channels VSN16R ultimately results in the reduction of hyperexcitability seen in individuals who suffer from seizures. The compiled data reveals that cannabinoids or compounds structurally similar to cannabinoids may prove useful in the treatment of seizures or epileptic disorders, similar to the cannabinol-based Epidiolex® medication for rare forms of epilepsy, reducing the chance of a seizure or minimizing its duration. Further research is needed to aid the development of more readily available [cannabis-based therapies](https://cedclinic.com/cannabinoids-inhibit-keratinocyte-proliferation-non-cb1-cb2/) for seizure activity and more general forms of epilepsy. Highlighting in this article are the options for treatment that the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) provides us, even in the absence of naturally occurring cannabinoids. If structurally similar compounds like VSN16R are able to be synthesized and proven effective, it could mean novel therapies could be developed even while red tape surrounds cannabis. The [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) affects a myriad of systems within the human body and is severely under-researched considering its potential. Epidiolex® is the only cannabinoid-based medication currently approved by the federal government but cannabis has shown promise in so many other areas where the current treatment is either ineffective or lacking. Research utilizing the endocannabinoid system as a target should continue and be pushed to the forefront of the medical community. The study is available for review or download here: [DOWNLOAD & REVIEW HERE](https://www.cedfoundation.com/wp-content/uploads/2020/03/The-Cannabinoid-Like-Compound-VSN16R-Acts-on-Large-Conductance-Ca2-Activated-K-Channels-to-Modulate-Hippocampal-CA1-Pyramidal-Neuron-Firing.pdf) View more studies like this in the CED Foundation Archive: [http://bit.ly/drcaplan](https://bit.ly/drcaplan) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabidiol as a New Treatment for Rare Forms of Epilepsy](https://cedclinic.com/cannabidiol-for-epilepsy-treatment-rare-forms/) Learn about cannabidiol's role as a treatment option for rare epilepsy forms and its clinical implications. [Read More](https://cedclinic.com/cannabidiol-for-epilepsy-treatment-rare-forms/) [Cannabinoid Pain Relief: Sodium Channel Modulation Research](https://cedclinic.com/cannabinoid-pain-relief-sodium-channel-modulation-research/) Explore research on cannabinoid modulation of sodium channels and its potential for pain relief therapies. [Explore Research](https://cedclinic.com/cannabinoid-pain-relief-sodium-channel-modulation-research/) [Endocannabinoid System Research: Cannabis Mental Health Care](https://cedclinic.com/clinical-trial-cannabis-mental-health-research/) Discover how endocannabinoid system research is advancing cannabis-based [mental health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/) treatments. [Discover More](https://cedclinic.com/clinical-trial-cannabis-mental-health-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=A%20Cannabinoid-Like%20Compound%20Modulates%20Neuronal%20Excitability%2C%20May%20Reduce%20Seizures&url=https%3A%2F%2Fcedclinic.com%2Fcannabinoid-like-compound-seizure-reduction%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabinoid-like-compound-seizure-reduction%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=A%20Cannabinoid-Like%20Compound%20Modulates%20Neuronal%20Excitability%2C%20May%20Reduce%20Seizures%20https%3A%2F%2Fcedclinic.com%2Fcannabinoid-like-compound-seizure-reduction%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).